Comparative Pharmacology
Head-to-head clinical analysis: PIRMELLA 1 35 versus SIMPESSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIRMELLA 1 35 versus SIMPESSE.
PIRMELLA 1/35 vs SIMPESSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Additionally, causes cervical mucus thickening and endometrial atrophy, reducing sperm penetration and implantation.
Simpesse is a combination estrogen-progestin oral contraceptive that suppresses gonadotropin release, primarily inhibiting ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis. Additionally, it alters cervical mucus viscosity and endometrial receptivity.
One tablet orally once daily for 21 days, followed by 7 placebo tablets during the withdrawal bleed.
Oral: 10 mg once daily, taken at least 1 hour before a meal.
None Documented
None Documented
Terminal half-life 24–30 hours for ethinyl estradiol; 13–18 hours for norethindrone. Steady state reached after 7–10 days.
Terminal elimination half-life is 24 hours (range 20-28 hours), supporting once-daily dosing.
Renal 60–80% as metabolites (glucuronide conjugates), biliary/fecal 10–20%.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism produces inactive metabolites that are excreted renally (20-30%) and fecally (<10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive